{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:45:13Z","timestamp":1789760713705,"version":"4.0.1"},"reference-count":32,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: SMARCA4-deficient or SMARCA4-mutated cancers are rare but highly aggressive tumors with poor differentiation, resistance to conventional treatments, and limited clinical guidance. While thoracic SMARCA4-deficient undifferentiated tumors are relatively well described, the full spectrum of SMARCA4-altered cancers across different organs and their therapeutic responses remains poorly understood. This study aimed to systematically review published case reports and case series to clarify the clinical characteristics, molecular features, treatment patterns, and survival outcomes of SMARCA4-altered malignancies. Methods: We conducted a systematic review of case reports and case series published between 2015 and 2025 using PubMed, Embase, and Web of Science. Eligible studies included adult patients with immunohistochemically or genetically confirmed SMARCA4-deficient or SMARCA4-mutated tumors. Key clinical, pathological, molecular, therapeutic, and outcome-related data were extracted. Descriptive statistics were used, and exploratory subgroup analyses were performed based on tumor type and treatment modality. The review protocol was registered in PROSPERO (CRD420251088805). Results: A total of 109 studies reporting 160 individual patients were included. Most tumors arose in the thorax (40.0%), followed by gastrointestinal (17.5%) and gynecologic sites (15.6%). The median age was 58 years, with a male predominance (70.0%) and frequent smoking history (44.4%). Platinum-based chemotherapy was administered in 62.5% of cases, and immune checkpoint inhibitors (ICIs) were used in 25.6%. Among ICI-treated patients, partial responses or stable disease were observed in 80.5%. The median progression-free survival (PFS) was 4.0 months, and the median overall survival (OS) was 5.0 months. Conclusions: SMARCA4-altered cancers are clinically and molecularly diverse but uniformly aggressive, with limited therapeutic benefit from conventional chemotherapy. Immune checkpoint inhibitors may offer improved outcomes in select patients, particularly those with thoracic tumors. Early molecular profiling, rare tumor registries, and biomarker-driven trials are crucial for guiding future treatment strategies.<\/jats:p>","DOI":"10.3390\/cancers17162675","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:31:37Z","timestamp":1755516697000},"page":"2675","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Characteristics and Outcomes of SMARCA4-Mutated or Deficient Malignancies: A Systematic Review of Case Reports and Series"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-091X","authenticated-orcid":false,"given":"Ryuichi","family":"Ohta","sequence":"first","affiliation":[{"name":"Department of Community Care, Unnan City Hospital, Unnan 699-1221, Shimane, Japan"},{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Osaka, Japan"},{"name":"Community Medicine Management, Shimane University Faculty of Medicine, Izumo 693-8501, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Community Care, Unnan City Hospital, Unnan 699-1221, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-1368","authenticated-orcid":false,"given":"Kaoru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-5161","authenticated-orcid":false,"given":"Chiaki","family":"Sano","sequence":"additional","affiliation":[{"name":"Community Medicine Management, Shimane University Faculty of Medicine, Izumo 693-8501, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-5587","authenticated-orcid":false,"given":"Hidetoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","article-title":"SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy","volume":"20","author":"Mardinian","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1038\/s41467-020-19402-8","article-title":"Functional Characterization of SMARCA4 Variants Identified by Targeted Exome-Sequencing of 131,668 Cancer Patients","volume":"11","author":"Fernando","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217811","DOI":"10.1016\/j.canlet.2025.217811","article-title":"SMARCA4: Promises and Challenges in the Treatment of Cancers","volume":"625","author":"Ye","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s11748-021-01627-z","article-title":"SMARCA4-Deficient Thoracic Sarcoma Revealed by Metastasis to the Small Intestine: A Diagnostic Dilemma","volume":"69","author":"Khanchel","year":"2021","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"216022","DOI":"10.1016\/j.canlet.2022.216022","article-title":"SMARCA4: Current Status and Future Perspectives in Non-Small-Cell Lung Cancer","volume":"554","author":"Tian","year":"2023","journal-title":"Cancer Lett."},{"key":"ref_6","first-page":"e30708","article-title":"SMARCA4-Deficient Undifferentiated Tumor: A Rare Malignancy with Distinct Clinicopathological Characteristics","volume":"14","year":"2022","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1002\/cam4.6083","article-title":"Clinical Characteristics and Prognostic Analysis of SMARCA4-Deficient Non-Small Cell Lung Cancer","volume":"12","author":"Liang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.1200\/JCO.2023.41.16_suppl.9049","article-title":"Thoracic SMARCA4-Deficient Cancer Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database","volume":"41","author":"Powell","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Longo, V., Catino, A., Montrone, M., Montagna, E.S., Pesola, F., Marech, I., Silvestris, N., Santini, D., and Cives, M. (2024). Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063237"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1177\/00031348221146972","article-title":"Identification and Treatment of SMARCA4-Deficient Poorly Differentiated Gastric Carcinoma","volume":"89","author":"Bhat","year":"2022","journal-title":"Am. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the Freely Available Easy-to-Use Software \u2018EZR\u2019 for Medical Statistics","volume":"48","author":"Kanda","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/jnen\/nlae039","article-title":"SMARCA4-Deficient Central Nervous System Metastases: A Case Series and Systematic Review","volume":"83","author":"Morris","year":"2024","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_14","first-page":"100476","article-title":"Thoracic SMARCA4-Deficient Undifferentiated Tumor with ALK Fusion Treated with Alectinib Achieved Remarkable Tumor Regression: Case Report","volume":"4","author":"Sheng","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.70352\/scrj.cr.24-0070","article-title":"Mesenteric SMARCA2-Deficient Yet SMARCA4-Preserved Aggressive Undifferentiated Tumor: A Case Report","volume":"11","author":"Tamaki","year":"2025","journal-title":"Surg. Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/modpathol.2017.61","article-title":"SMARCA4-Deficient Thoracic Sarcoma: A Distinctive Clinicopathological Entity with Undifferentiated Rhabdoid Morphology and Aggressive Behavior","volume":"30","author":"Sauter","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"217282","DOI":"10.1016\/j.canlet.2024.217282","article-title":"SMARCA4 and SMARCA2 Co-Deficiency: An Uncommon Molecular Signature Defining a Subset of Rare, Aggressive and Undifferentiated Malignancies Associated with Defective Chromatin Remodeling","volume":"605","author":"Field","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102185","DOI":"10.1016\/j.labinv.2024.102185","article-title":"Switch\/Sucrose Nonfermentable-Deficient Tumors\u2014Morphology, Immunophenotype, Genetics, Epigenetics, Nosology, and Therapy","volume":"105","author":"Ng","year":"2025","journal-title":"Lab. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Manolakos, P., Boccuto, L., and Ivankovic, D. (2024). A Critical Review of the Impact of SMARCA4 Mutations on Survival Outcomes in Non-Small Cell Lung Cancer. J. Pers. Med., 14.","DOI":"10.3390\/jpm14070684"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s12029-024-01060-4","article-title":"SMARCA4-Deficient Undifferentiated Esophageal Carcinoma: A Clinical Case Series and Literature Review","volume":"55","author":"Shweikeh","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15330338251345377","DOI":"10.1177\/15330338251345377","article-title":"Retrospective Insights into the Clinicopathological Features and Treatment Outcomes of Thoracic SMARCA4-Deficient Tumors","volume":"24","author":"Chen","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108644","DOI":"10.1016\/j.lungcan.2025.108644","article-title":"Acquired SMARCA4 Alterations: An Uncommon Contributor to Cancer Progression in Lung Adenocarcinomas","volume":"206","author":"Alessi","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41467-020-19328-1","article-title":"Role of Specialized Composition of SWI\/SNF Complexes in Prostate Cancer Lineage Plasticity","volume":"11","author":"Cyrta","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/jcp-2024-209619","article-title":"Unravelling Switch\/Sucrose Non-Fermentable (SWI-SNF) Complex-Deficient Thoracic Tumours: A Clinicopathological Comparative on Undifferentiated Tumours and Non-Small Cell Lung Carcinomas with BRG1 and BRM Deficiency","volume":"78","author":"Sood","year":"2024","journal-title":"J. Clin. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yamashita, K., Sewastjanow-Silva, M., Yoshimura, K., Rogers, J.E., Vicentini, E.R., Pizzi, M.P., Fan, Y., Zou, G., Li, J.J., and Murphy, M.B. (2024). SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel. Cancers, 16.","DOI":"10.3390\/cancers16071300"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","article-title":"Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer","volume":"14","author":"Yatabe","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e36959","DOI":"10.1097\/MD.0000000000036959","article-title":"Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient and TP53 Mutant Undifferentiated Lung Cancer","volume":"103","author":"Chen","year":"2024","journal-title":"Medicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.21037\/jtd-2025-541","article-title":"SMARCA4-Deficient Undifferentiated Thoracic Tumor: A Case Report and Literature Review","volume":"17","author":"Liu","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.chembiol.2024.09.004","article-title":"Enhancer Reprogramming Underlies Therapeutic Utility of a SMARCA2 Degrader in SMARCA4 Mutant Cancer","volume":"31","author":"Kotagiri","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1038\/s41467-022-34562-5","article-title":"Selective PROTAC-Mediated Degradation of SMARCA2 Is Efficacious in SMARCA4 Mutant Cancers","volume":"13","author":"Cantley","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/cas.14311","article-title":"Synthetic Lethal Therapy Based on Targeting the Vulnerability of SWI\/SNF Chromatin Remodeling Complex-Deficient Cancers","volume":"111","author":"Sasaki","year":"2020","journal-title":"Cancer Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2675\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:29:12Z","timestamp":1760034552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":32,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17162675"],"URL":"https:\/\/doi.org\/10.3390\/cancers17162675","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]}}}